Enrique Cardenas Ramos, MD
Family Medicine · Gallatin, TNNPI 1760821953
Payments from drug & device makers
Across 311 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Pfizer$649
- AstraZeneca$429
- Lilly USA, LLC$341
- Amgen$300
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,000100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $1,641 |
| AbbVie(2 entities) | 86 | $1,107 |
| Pfizer | 37 | $649 |
| AstraZeneca | 13 | $429 |
| Lilly USA, LLC | 17 | $341 |
| Amgen | 19 | $300 |
| GSK | 12 | $227 |
| Astellas Pharma US Inc | 6 | $201 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $119 |
| Sumitomo Pharma America, Inc. | 7 | $112 |
| Phathom Pharmaceuticals, Inc. | 5 | $95 |
| Abbott | 1 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $80 |
| Exact Sciences | 4 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Johnson & Johnson | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Bausch Health US, LLC | 2 | $43 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Dynavax Technologies Corporation | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Dexcom, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Novartis | 1 | $22 |
| Harmony Biosciences LLC | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,000 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 90 | $102,549 |
| OzempicSemaglutide | 68 | $100,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $32,239 |
| MounjaroTirzepatide | 14 | $23,245 |
| FarxigaDapagliflozin Propanediol | 14 | $19,029 |
| GemtesaVibegron | 14 | $18,389 |
| EliquisApixaban | 16 | $17,224 |
| TrulicityDulaglutide | 14 | $16,598 |
| XareltoRivaroxaban | 11 | $12,489 |
| Duloxetine Hcl | 59 | $8,067 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,613 |
| Cyclosporine | 12 | $3,798 |
| Omeprazole | 122 | $2,568 |
| Varenicline Tartrate | 12 | $2,553 |
| Atorvastatin Calcium | 194 | $2,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $102,54990 claims |
| Novo NordiskOzempic | $1,641 | $100,85268 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $227 | $39,85141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $341 | $39,84328 claims |
| AstraZenecaFarxiga | $429 | $19,02914 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $112 | $18,38914 claims |
| PfizerEliquis | $649 | $17,22416 claims |
| Johnson & JohnsonXarelto | $56 | $12,48911 claims |
| AbbVieSynthroid | $1,107 | $1,37728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Gallatin
- Kymberly MoyerGallatin$5.9M
- Rickey ManningKnoxville$8.1M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.